Comparative Pharmacology
Head-to-head clinical analysis: INFLAMASE MILD versus PREDSULFAIR II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFLAMASE MILD versus PREDSULFAIR II.
INFLAMASE MILD vs PREDSULFAIR II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inflammase Mild is a combination product containing hydrocortisone, a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis. It also contains benzalkonium chloride, a quaternary ammonium compound with antiseptic properties.
Prednisolone is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators. Sulfonamide component provides bacteriostatic action via inhibition of dihydropteroate synthase in bacterial folate synthesis.
N/A
1-2 drops into the affected eye(s) every 4-6 hours; not to exceed 6 doses per day.
None Documented
None Documented
1.5-2.5 hours; short half-life allows frequent dosing for mild inflammation.
Terminal elimination half-life of prednisolone (active moiety): 2.1-3.5 hours; clinical context: duration of HPA axis suppression exceeds plasma half-life (12-36 hours).
Renal excretion of unchanged drug (approximately 60%) and glucuronide conjugate (20%); biliary/fecal (15%).
Renal: 70-80% (30-50% as unchanged prednisolone, 20-30% as prednisone and inactive metabolites); Biliary/Fecal: 15-20%
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Sulfonamide Combination